Fig. 3
From: Metabolic reprogramming: the emerging concept and associated therapeutic strategies
Iatrogenic activation of CSCs with altered metabolic reprogramming. Non-CSCs are susceptible to chemotherapy and undergo apoptosis. Released PGE2 awakens the dormant CSCs localized in the niche. Proliferating CSCs are likely to exhibit additional metabolic reprogramming, concomitant with up-regulation of OXPHOS-related molecules
